We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+7.72%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$357M
AUM Growth
+$14.3M
Cap. Flow
-$377K
Cap. Flow %
-0.11%
Top 10 Hldgs %
60.48%
Holding
73
New
21
Increased
19
Reduced
16
Closed
11

Top Buys

Rank Stock Value
1
ENSG icon
The Ensign Group
ENSG
+$7.79M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.69M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$6.13M
4
ILMN icon
Illumina
ILMN
+$5.94M
5
CNC icon
Centene
CNC
+$4.1M

Top Sells

Rank Stock Value
1
NUVA
NuVasive, Inc.
NUVA
+$14.1M
2
AMRN
Amarin Corp
AMRN
+$9.2M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$8.15M
4
ABMD
Abiomed Inc
ABMD
+$7.81M
5
AERI
Aerie Pharmaceuticals
AERI
+$5.45M

Sector Composition

Rank Sector Weight
1 Healthcare 82.49%
2 Industrials 9.51%
3 Financials 4.31%
4 Miscellaneous 1.99%
5 Real Estate 1.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCM
1
DELISTED
R1 RCM Inc. Common Stock
RCM
$34M 9.51%
2,699,159
-264,500
-9% -$2.99M
AMRN
2
Amarin Corp
AMRN
$295M
$30.2M 8.46%
77,903
-25,111
-24% -$9.2M
GSK icon
3
GSK
GSK
$102B
$28.1M 7.87%
554,948
-87,600
-14% -$4.4M
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
$25.6M 7.18%
536,794
+41,365
+8% +$1.67M
DHR icon
5
Danaher
DHR
$152B
$20.8M 5.81%
163,677
-15,409
-9% -$1.82M
ENSG icon
6
The Ensign Group
ENSG
$10.1B
$17.4M 4.87%
326,561
+156,007
+91% +$7.79M
RDUS
7
DELISTED
Radius Health, Inc.
RDUS
$17.3M 4.85%
710,517
+65,100
+10% +$1.42M
ASND icon
8
Ascendis Pharma A/S
ASND
$16.3B
$15.7M 4.4%
136,397
+33,101
+32% +$3.96M
EHTH icon
9
eHealth
EHTH
$38.4M
$15.4M 4.31%
178,739
-21,910
-11% -$1.47M
SNY icon
10
Sanofi
SNY
$107B
$11.5M 3.22%
266,062
-66,340
-20% -$2.82M
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$137B
$10.6M 2.97%
57,849
+19,620
+51% +$3.43M
TGTX icon
12
TG Therapeutics
TGTX
$8.26B
$7.64M 2.14%
883,501
+134,907
+18% +$1.02M
DCPH
13
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$6.88M 1.93%
305,233
+54,801
+22% +$1.28M
ARGX icon
14
argenx
ARGX
$64B
$6.83M 1.91%
48,264
+8,930
+23% +$1.13M
ILMN icon
15
Illumina
ILMN
$32.6B
$6.73M 1.89%
+18,802
New +$5.94M
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$31.7B
$6.32M 1.77%
+87,140
New +$6.69M
BOLD
17
DELISTED
Audentes Therapeutics, Inc
BOLD
$6.04M 1.69%
+159,526
New +$6.13M
NUVA
18
DELISTED
NuVasive, Inc.
NUVA
$5.37M 1.5%
91,798
-238,803
-72% -$14.1M
CNC icon
19
Centene
CNC
$32B
$5.22M 1.46%
99,600
+76,000
+322% +$4.1M
ZGNX
20
CALL
DELISTED
Zogenix, Inc.
ZGNX
$4.98M 1.4%
+104,300
New +$4.2M
ARQL
21
DELISTED
Arqule Inc
ARQL
$4.97M 1.39%
451,688
-195,230
-30% -$1.36M
FATE icon
22
Fate Therapeutics
FATE
$291M
$4.42M 1.24%
217,856
-132,155
-38% -$2.38M
ARNA
23
DELISTED
Arena Pharmaceuticals Inc
ARNA
$4.31M 1.21%
73,501
-2,220
-3% -$115K
DERM
24
DELISTED
Dermira, Inc.
DERM
$3.82M 1.07%
399,874
+220,374
+123% +$2.37M
TCDA
25
DELISTED
Tricida, Inc. Common Stock
TCDA
$3.46M 0.97%
87,568
+38,060
+77% +$1.34M
1
2 3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2019 Portfolio in Review

As of Q2 2019, Eversept Partners held 73 positions worth $357M, up 4.2% from $343M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Eversept Partners's Q2 2019 filing shows 21 new, 19 increased, 16 reduced and 11 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 87,140 shares worth $6.32M. The largest sale was NuVasive, Inc., an estimated $14.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 86% a quarter earlier, followed by Industrials and Financials.

  • Eversept Partners's largest Q2 2019 buy was Alnylam Pharmaceuticals: 87,140 shares worth $6.32M.
  • Eversept Partners added most to The Ensign Group in Q2 2019, an estimated $7.79M increase.
  • Eversept Partners's biggest Q2 2019 reduction was NuVasive, Inc., cutting an estimated $14.1M.
  • Eversept Partners fully exited Abiomed Inc in Q2 2019, selling an estimated $7.81M.
  • Eversept Partners's ten largest holdings make up 60% of its $357M portfolio in Q2 2019.
  • Eversept Partners opened 21 new positions and closed 11 in Q2 2019.
  • Eversept Partners's portfolio value rose 4.2% quarter-over-quarter to $357M.

Based on Eversept Partners's 13F filing for Q2 2019, filed 13 Aug 2019.